Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Specific BCRABL1 Inhibitor, Plus Imatinib in Previously Treated CML

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Moshe Talpaz
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Moshe Talpaz
16 views
November 18, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

19:39
Pfizer Hematology

The First Treatment Choice Matters

Feat. A. Ip
Chronic Myeloid Leukemia
17:08

CML State of the Art 2019: 2nd Generation TKIs Improve Molecular Out…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

J. Cortés

28 views
15:28

Therapeutic Innovations in CML: Reducing Toxicity w/ Optimized Front…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Deininger

14 views
18:37

Impact of Depth and Duration of Response of TFR in CML: Current Reco…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

D. Rea

11 views
12:22

Impact of Comorbidities in Treatment Choice of CML: TKI Toxicities N…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

T. Hughes

104 views
15:19

29 y/o Male w/ CML: Allograft vs. 3rd Line Therapy - Transplant Is A…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Mauro

16 views
08:01

CML-044 ENESTop 192-Weeks Results on Treatment-Free Remission in Chr…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

T. Hughes

11 views
13:11

Phase 1 CML-041 Results on Combination of Asciminib, a Novel and Spe…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

M. Talpaz

16 views